These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12837670)

  • 21. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol.
    Pelton GH; Devanand DP; Bell K; Marder K; Marston K; Liu X; Cooper TB
    Am J Geriatr Psychiatry; 2003; 11(2):186-93. PubMed ID: 12611748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
    Barak Y; Plopski I; Tadger S; Paleacu D
    Int Psychogeriatr; 2011 Nov; 23(9):1515-9. PubMed ID: 21492498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men.
    Loebl T; Angarita GA; Pachas GN; Huang KL; Lee SH; Nino J; Logvinenko T; Culhane MA; Evins AE
    J Clin Psychiatry; 2008 Mar; 69(3):480-6. PubMed ID: 18294021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
    De Deyn PP; Carrasco MM; Deberdt W; Jeandel C; Hay DP; Feldman PD; Young CA; Lehman DL; Breier A
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):115-26. PubMed ID: 14758577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial.
    Culo S; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Pollock BG
    Alzheimer Dis Assoc Disord; 2010; 24(4):360-4. PubMed ID: 20625270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
    Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
    N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
    J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
    Devanand DP; Mintzer J; Schultz S; Sultzer D; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Andrews H; Levin B
    Am J Geriatr Psychiatry; 2012 Apr; 20(4):362-73. PubMed ID: 21407047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
    Schneider LS; Tariot PN; Lyketsos CG; Dagerman KS; Davis KL; Davis S; Hsiao JK; Jeste DV; Katz IR; Olin JT; Pollock BG; Rabins PV; Rosenheck RA; Small GW; Lebowitz B; Lieberman JA
    Am J Geriatr Psychiatry; 2001; 9(4):346-60. PubMed ID: 11739062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
    Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
    Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances.
    Suh GH; Son HG; Ju YS; Jcho KH; Yeon BK; Shin YM; Kee BS; Choi SK
    Am J Geriatr Psychiatry; 2004; 12(5):509-16. PubMed ID: 15353389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients.
    Lee YM; Park JM; Lee BD; Moon E; Jeong HJ; Chung YI; Kim JH; Kim HJ; Mun CW; Kim TH; Kim YH
    J Clin Psychiatry; 2016 Jan; 77(1):e8-13. PubMed ID: 26845282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.
    Rosenheck RA; Leslie DL; Sindelar JL; Miller EA; Tariot PN; Dagerman KS; Davis SM; Lebowitz BD; Rabins P; Hsiao JK; Lieberman JA; Schneider LS;
    Arch Gen Psychiatry; 2007 Nov; 64(11):1259-68. PubMed ID: 17984395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
    Kurlan R; Cummings J; Raman R; Thal L;
    Neurology; 2007 Apr; 68(17):1356-63. PubMed ID: 17452579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The management of psychogeriatric patient.
    Zannino G; Gargiulo A; Lamenza F; Marotta MG; Barzotti T; Silvestri A; Ettorre E; Marigliano V
    Arch Gerontol Geriatr Suppl; 2004; (9):465-70. PubMed ID: 15207448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
    Kurz A; Schwalen S S; Schmitt A
    Int Psychogeriatr; 2005 Dec; 17(4):605-16. PubMed ID: 16185378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.
    van Nimwegen L; de Haan L; van Beveren N; Laan W; van den Brink W; Linszen D
    J Clin Psychopharmacol; 2008 Apr; 28(2):214-8. PubMed ID: 18344733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias.
    Grossman F; Okamoto A; Turkoz I; Gharabawi G
    J Am Geriatr Soc; 2004 May; 52(5):852-3. PubMed ID: 15086685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.